Ooms, F. (2023). The Entrepreneurial Cognitive Flexibility. A Study at the Intersection of Neuroscience and Entrepreneurship [Doctoral thesis, ULiège - University of Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/301474 |
Ooms, F., Annen, J., Panda, R., Cecconi, B., Surlemont, B., & Laureys, S. (November 2024). Entrepreneurial neuroanatomy: Exploring gray matter volume in habitual entrepreneurs. Journal of Business Venturing Insights, 22, 00480. doi:10.1016/j.jbvi.2024.e00480 |
Ooms, F., Annen, J., Panda, R., Meunier, P., Tshibanda, L., Laureys, S., Pollack, J. M., & Surlemont, B. (March 2024). Advancing (Neuro)Entrepreneurship Cognition Research Through Resting-State fMRI: A Methodological Brief. Entrepreneurship: Theory and Practice, 48 (2), 719-741. doi:10.1177/10422587231170217 |
Ooms, F., Surlemont, B., Annen, J., Panda, R., & Laureys, S. (August 2023). The Habitual Entrepreneur Brain – A Voxel Based Morphometry Study. Academy of Management Proceedings, 2023 (1). doi:10.5465/amproc.2023.142bp |
Hoveyda, H. R., Fraser, G. L., Zoute, L., Dutheuil, G., Schils, D., Brantis, C., Lapin, A., Parcq, J., Guitard, S., Lenoir, F., Bousmaqui, M. E., Rorive, S., Hospied, S., Blanc, S., Bernard, J., Ooms, F., McNelis, J. C., & Olefsky, J. M. (01 October 2018). N-Thiazolylamide-based free fatty-acid 2 receptor agonists: Discovery, lead optimization and demonstration of off-target effect in a diabetes model. Bioorganic and Medicinal Chemistry, 26 (18), 5169 - 5180. doi:10.1016/j.bmc.2018.09.015 |
Ferain, T., Hoveyda, H., Ooms, F., Schols, D., Bernard, J., & Fraser, G. (June 2011). Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication. Journal of Pharmacology and Experimental Therapeutics, 337 (3), 655 - 662. doi:10.1124/jpet.111.179622 |
Frédérick, R., Dumont, W., Ooms, F., Aschenbach, L., Van der Schyf, C. J., Castagnoli, N., Wouters, J., & Krief, A. (15 June 2006). Synthesis, structural reassignment, and biological activity of type B MAO inhibitors based on the 5H-indeno[1,2-c]pyridazin-5-one core. Journal of Medicinal Chemistry, 49 (12), 3743 - 3747. doi:10.1021/jm051091j |
Frédérick, R., Norberg, B., Durant, F., Ooms, F., & Wouters, J. (September 2004). Three 5H-indeno[1,2-c]pyridazin-5-one derivatives, potent type-B monoamine oxidase inhibitors. Acta Crystallographica. Section C, Crystal Structure Communications, 60 (Pt 9), 623 - o626. doi:10.1107/S0108270104014660 |
Ooms, F., Frédérick, R., Durant, F., Petzer, J. P., Castagnoli, N., Van der Schyf, C. J., & Wouters, J. (06 January 2003). Rational approaches towards reversible inhibition of type B monoamine oxidase. Design and evaluation of a novel 5H-Indeno[1,2-c]pyridazin-5-one derivative. Bioorganic and Medicinal Chemistry Letters, 13 (1), 69 - 73. doi:10.1016/s0960-894x(02)00838-7 |
Ooms, F., Weber, P., Carrupt, P. A., & Testa, B. (18 July 2002). A simple model to predict blood-brain barrier permeation from 3D molecular fields. Biochimica et Biophysica Acta, 1587 (2-3), 118 - 125. doi:10.1016/s0925-4439(02)00074-1 |
Ooms, F., Wouters, J., Oscari, O., Happaerts, T., Bouchard, G., Carrupt, P.-A., Testa, B., & Lambert, D. M. (25 April 2002). Exploration of the pharmacophore of 3-alkyl-5-arylimidazolidinediones as new CB(1) cannabinoid receptor ligands and potential antagonists: synthesis, lipophilicity, affinity, and molecular modeling. Journal of Medicinal Chemistry, 45 (9), 1748 - 1756. doi:10.1021/jm010896y |
Brühlmann, C., Ooms, F., Carrupt, P.-A., Testa, B., Catto, M., Leonetti, F., Altomare, C., & Carotti, A. (13 September 2001). Coumarins derivatives as dual inhibitors of acetylcholinesterase and monoamine oxidase. Journal of Medicinal Chemistry, 44 (19), 3195 - 3198. doi:10.1021/jm010894d |
Wouters, J., & Ooms, F. (May 2001). Small molecule crystallography in drug design. Current Pharmaceutical Design, 7 (7), 529 - 545. doi:10.2174/1381612013397889 |
Ooms, F. (February 2000). Molecular modeling and computer aided drug design. Examples of their applications in medicinal chemistry. Current Medicinal Chemistry, 7 (2), 141 - 158. doi:10.2174/0929867003375317 |
Ooms, F., Delvosal, S., Wouters, J., Durant, F., Dockendolf, G., Van't Land, C., Glass, T., Castagnoli Jr., N., & Van Der Schyf, C. J. (2000). Empirical and molecular modeling study of the pyridinium species RHPP+, an abundant and potentially neurotoxic metabolite of haloperidol. Journal of the Chemical Society. Perkin Transactions 2, (9), 1781 - 1787. doi:10.1039/b002357o |
Ooms, F., Jegham, S., George, P., Durant, F., & Wouters, J. (2000). Molecular interaction between reversible MAO-A inhibitors and the enzyme. Application to aryloxazolidinone, a prototype series. Neurobiology, 8 (1), 81 - 98. |
Ooms, F., Wouters, J., Collin, S., Durant, F., Jegham, S., & George, P. (02 June 1998). Molecular lipophilicity potential by CLIP, a reliable tool for the description of the 3D distribution of lipophilicity: application to 3-phenyloxazolidin-2-one, a prototype series of reversible MAOA inhibitors. Bioorganic and Medicinal Chemistry Letters, 8 (11), 1425 - 1430. doi:10.1016/s0960-894x(98)00230-3 |
Bousbaa, J., Ooms, F., & Krief, A. (27 October 1997). γ-Siloxy-benzyllithiums: Stereochemistry of the retro-[1,4]-Brook rearrangement. Tetrahedron Letters, 38 (43), 7625 - 7628. doi:10.1016/S0040-4039(97)01810-8 |
Wouters, J., Ooms, F., & Durant, F. (15 July 1997). 2-oxazolidinone. Acta Crystallographica. Section C, Crystal Structure Communications, 53 (7), 895 - 897. doi:10.1107/S0108270197003752 |
Ooms, F., Wouters, J., Durant, F., Castagnoli Jr., N., Van't Land, C., Dockendolf, G., Glass, T., & Van Der Schyf, C. J. (1997). Conformational distribution of the potentially neurotoxic metabolite of haloperidol, HPP+, by NMR spectroscopy, X-ray crystallography and molecular dynamics simulations. Journal of the Chemical Society. Perkin Transactions 2, (12), 2627 - 2632. doi:10.1039/a705037b |
Wouters, J., Ooms, F., Jegham, S., Koenig, J. J., George, P., & Durant, F. (1997). Reversible inhibition of type B monoamine oxidase. Theoretical study of model diazo heterocylic compounds. European Journal of Medicinal Chemistry, 32 (9), 721 - 730. doi:10.1016/S0223-5234(97)88914-3 |
Léonard, C., Ooms, F., & Surlemont, B. (2022). Entrepreneurs face à la crise. Au coeur du testing Covid Belge. Barchon, Belgium: L'attitude des Héros. |
Ooms, F., & Pirnay, F. (2024). Pokemón: Ethias’ corporate entrepreneurship initiative. In J. Schmutzler, L. Palacios-Chacón, S. Burvill, ... V. Andonova (Eds.), Teaching Cases on Entrepreneurship and Innovation: Unexplored Topics and Contexts. United States: Edward Elgar. doi:10.4337/9781802204537.00020 |
Ooms, F., & Falize, M. (2016). Le Business Model Canvas. In F. Janssen, Entreprendre-Une introduction à l'entrepreneuriat (2ième édition). Louvain-La-Neuve, Belgium: De Boeck Supérieur. |
Ooms, F., Vanderstraeten, J., Hendrik, S., & Thanh Phan, T. (2022). Global University Entrepreneurial Spirit Students’ Survey (GUESSS): 2021 Belgium National Report. Switzerland: Guess. https://orbi.uliege.be/handle/2268/267185 |
Antony, H., Alâadany, E., Le Petit, M., Collette, F., & Ooms, F. (2024). The Entrepreneurial Lens Of Decision-making And Opportunity Recognition: An Eye-tracking Study On Student Entrepreneurs [Paper presentation]. Belgian Entrepreneurship Research Day (BERD) 2024, Brussels, Belgium. |
Ooms, F., Annen, J., Panda, R., Surlemont, B.* , LAUREYS, S.* , TSHIBANDA, L., Meunier Paul, & Jeffrey Pollack*. (15 June 2022). Using the Brain’s Functional Connectivity to Explore Serial Entrepreneurs’ and Managers’ Cognitive Flexibility [Paper presentation]. EURAM2022, Zurich, Switzerland. |
Ooms, F., & Laureys, S. (08 June 2021). The entrepreneurial Brain [Paper presentation]. Babson Entrepreneurship Research Conference BCERC2021. |
Ooms, F. (10 January 2022). Neuroentrepreneurship a call from the discipline: nascent evidence from resting-state fMRI [Paper presentation]. Giga CRC group meeting, Liège, Belgium. |
Ooms, F. (16 November 2021). Décrypter le cerveau entrepreneurial [Paper presentation]. Le Grand Saut, Canada. |
Ooms, F., Lerner, D., Pollack, J., & Surlemont, B. (28 October 2021). Beyond Entry: Exploring Entrepreneurs’ Self-Reported ADHD Symptoms in Nascent, Early, and Established Ventures [Paper presentation]. Belgian Entrepreneurship Research Day BERD2021, Hasselt, Belgium. |
Antony, H., Alâadany, E., Le Petit, M., Ooms, F., & Collette, F. (30 May 2024). Decoding entrepreneurial decision-making through eye tracking: Preliminary Results [Poster presentation]. The Annual Conference of Belgian Association for Psychological Sciences (BAPS), Brussels, Belgium. |
Ooms, F., Collette, F., Laureys, S., & Surlemont, B. (August 2023). Navigating the entrepreneurial mind: the influence of stress and well-being on cognitive flexibility [Poster presentation]. Academy of Management, Boston, United States. |
Ooms, F., & Mastrogiorgio, A. (17 June 2023). Intrinsic brain activity in organizational neuroscience [Poster presentation]. Academy Of Management - Organizational Neuroscience, Rotterdam, Netherlands. |
Ooms, F., & Pollack, J. (05 August 2022). Entrepreneur stress and cognitive Flexibility [Poster presentation]. AOM 2022 Seattle, Seattle, United States. |
Magnier, L., & Ooms, F. (2023). L’entrepreneuriat : du profit à la planète. La Libre Belgique. |
Ooms, F., & Surlemont, B. (2023). Entrepreneurs : un cerveau différent ? Cerveau & Psycho, (159). |
Ooms, F., & Surlemont, B. (2022). Pour un entrepreneuriat à impact. La Libre Belgique. |
Ooms, F., & Céline, L. (2021). Avoir deux mains droites. Libre Eco. |